Abstract
1. We have utilised a new non-imaging echo-Doppler cardiac output device, using the principle of attenuated compensated volume flow (ACVF), to assess the cardiovascular effects of atenolol and buccal nitroglycerin (NTG) in a placebo-controlled study of 30 patients with coronary disease. 2. Atenolol (4 mg i.v.) reduced heart rate, cardiac output and time-averaged mean aortic velocity (P less than 0.01) and increased systemic vascular resistance (P less than 0.01). 3. Buccal NTG (5 mg) reduced systemic mean arterial pressure (P less than 0.01), cardiac stroke volume (P less than 0.05) and stroke length (P less than 0.01). 4. Thus although both drugs reduced time-averaged aortic velocity (an index of cardiac performance), the concomitant reduction in cardiac stroke length and tachycardia suggested sub-optimal cardiac filling for buccal NTG, whereas for atenolol (with the associated increased systemic vascular resistance but unchanged stroke length) attenuation of sympathetic stimulation at cardiac beta-adrenoceptors. 5. The ACVF method of cardiovascular monitoring should prove useful in human pharmacodynamic studies.
References
May 21, 1979·European Journal of Clinical Pharmacology·T L SvendsenJ Trap-Jensen
Jan 1, 1979·Ultrasonic Imaging·C F Hottinger, J D Meindl
Jan 1, 1978·Chest·P P SteeleR A Vogel
Jan 1, 1975·Circulation·J H McAnultyS H Rahimtoola
Mar 1, 1975·Circulation·D O WilliamsD T Mason
Oct 1, 1976·Chest·R ShahR H Helfant
Jan 1, 1989·Ultrasound in Medicine & Biology·J M EvansP N Wells
Jan 1, 1989·Ultrasound in Medicine & Biology·J M EvansP N Wells
Oct 17, 1989·The American Journal of Cardiology·B SilkeS H Taylor
Jan 1, 1988·British Journal of Anaesthesia·S H Taylor, B Silke
Sep 1, 1987·Critical Care Medicine·K D DonovanM Ireland
Nov 1, 1985·British Journal of Clinical Pharmacology·B SilkeS H Taylor
Jan 1, 1967·Circulation·M NajmiP Novack
Jan 1, 1971·The American Journal of Cardiology·J O ParkerS Di Giorgi
Jan 1, 1968·The American Journal of Cardiology·J O ParkerS Di Giorgi
Dec 1, 1982·European Heart Journal·S H TaylorA Hilal
Jul 1, 1981·Journal of Cardiovascular Pharmacology·B SilkeS H Taylor
Jan 1, 1984·British Heart Journal·H IhlenE Myhre
Feb 1, 1984·American Heart Journal·J A LoeppkyU C Luft
Dec 1, 1982·The American Journal of Cardiology·S J GoldbergY Carnahan
Mar 1, 1983·Circulation·L L HuntsmanE A Hessel
Feb 1, 1983·Circulation·U ElkayamW L Henry
Jan 1, 1982·Cardiovascular Research·S E Gisvold, A O Brubakk
Jan 1, 1981·European Journal of Clinical Pharmacology·W G HendryS H Taylor
Jul 1, 1965·British Heart Journal·B CHRISTENSSONH WESTLING
Citations
Sep 1, 1991·British Journal of Clinical Pharmacology·H W NgA M Breckenridge
May 1, 1993·British Journal of Clinical Pharmacology·H HinrichsenW Kirch
May 1, 1995·British Journal of Clinical Pharmacology·M SiepmannW Kirch
Jan 1, 1997·Journal of Clinical Pharmacology·C de Mey, K A Erb
Nov 1, 1996·Cardiovascular Drugs and Therapy·B SilkeF J Harrison
Mar 1, 1994·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·H Osuga, A M Hakim